IP Library Granted Patent US 12,622,904
Granted Patent B2
US 12,622,904 · App. 19/085,650 · Granted May 12, 2026

Buprenorphine dosing regimens

Inventors: Azmi Nasser (North Chesterfield, VA); Celine M. Laffont (North Chesterfield, VA); Christian A. Heidbreder (North Chesterfield, VA)
Assignee: INDIVIOR UK LIMITED
A61K31/485A61K9/0019A61K47/22A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,904
App. No.
19/085,650
Granted
May 12, 2026
Kind
B2
Abstract

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.

Claims (18)

1 . A method of treating moderate to severe opioid use disorder in an opioid-dependent human, the method comprising:

(a) administering to said opioid-dependent human, by subcutaneous injection once per month for a period of one to three months, a first composition comprising:

(i) about 14 wt % to about 22 wt % buprenorphine in the form of the free base;

(ii) about 22 wt % to about 42 wt % of a 50:50 to 80:20 poly(DL-lactide-co-glycolide) copolymer having an average molecular weight of about 5,000 Daltons to about 30,000 Daltons; and

(iii) about 40 wt % to about 60 wt % of N-methyl-2-pyrrolidone; and

(b) administering to said opioid-dependent human, by subcutaneous injection once per month beginning one month after the last dose of the first composition, a second composition comprising:

(i) about 14 wt % to about 22 wt % buprenorphine in the form of the free base;

(ii) about 22 wt % to about 42 wt % of a 50:50 to 80:20 poly(DL-lactide-co-glycolide) copolymer having an average molecular weight of about 5,000 Daltons to about 30,000 Daltons; and

(iii) about 40 wt % to about 60 wt % of N-methyl-2-pyrrolidone,

wherein the amount of buprenorphine in (a)(i) is greater than the amount of buprenorphine in (b)(i).

2 . The method according to claim 1 , wherein the amount of buprenorphine in (a)(i) is about 250 mg to about 350 mg.

3 . The method according to claim 2 , wherein the amount of buprenorphine in (b)(i) is about 80 mg to about 120 mg.

4 . The method according to claim 1 , wherein the amount of buprenorphine in (b)(i) is about 80 mg to about 120 mg.

5 . The method according to claim 1 , wherein the amount of buprenorphine in (b)(i) is about 300 mg.

6 . The method according to claim 1 , wherein the amount of buprenorphine in (b)(i) is 300 mg.

7 . The method according to claim 1 , wherein the amount of buprenorphine in (b)(i) is about 100 mg.

8 . The method according to claim 2 , wherein the amount of buprenorphine in (b)(i) is about 100 mg.

9 . The method according to claim 2 , wherein the amount of buprenorphine in (b)(i) is about 300 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2025
From: NASSER, AZMI; LAFFONT, CELINE M.; HEIDBREDER, CHRISTIAN
To: INDIVIOR UK LIMITED
Reel/Frame 070578/0212 →